Scientists at Encode Research (www.EncodeResearch.com) announced today that the U.S. Patent and Trademark Office issued a patent on their formulas for the safe delivery of Nitric Oxide (NO) to tissues and organs.

The scientist’s research and patents focus on genetically-targeted solutions for optimal health in humans, and include L-Arginine Nitric Oxide delivery systems. Their unique and patented L-arginine transport systems provide a specific signaling cell matrix designed to achieve appropriate cellular goals and provide health benefits, including mitigation of low L-arginine levels as evidenced in Dysregulated Arginine Metabolism (DAR).

Two of the Nitric Oxide (NO) patents and formulas, called NO FOR HEALTH, are exclusively licensed to Boresha International, and represents one of several technologies that Encode Research is developing for delivering NO to target tissues for therapeutic benefit.

Nitric Oxide (NO) is widely recognized as a key signaling molecule in human health and is associated with a variety of tissues and organs that affect cardiovascular disease, inflammatory disease and male erectile dysfunction.

Since its discovery as a signaling molecule 10 years ago, Nitric Oxide (NO) has been demonstrated to be ubiquitous and essential to a broad range of biological functions, but potentially dangerous in human use (Johns Hopkins/JAMA).

The issued patent broadly protects Encode Research’s L-Arginine formulas for nitric oxide delivery, and is considered the only long-term safe delivery system for the amino acid L-Arginine. The patent encompasses the only Nitric Oxide (NO) formulas that contain Blind Amino Acid® Riders, which render NO and L-Arginine safe for human use long-term.

Scientists at Encode Research have proven the long-term safety in humans of their L-Arginine NO patents over a 25-year period. This is the longest validated and proven use of L-Arginine/NO in the world.

The patented delivery molecules in the formulas contain nitric oxide donors, enabling potent biological effects and prolonged duration of action with a proven favorable safety profile.

The Nitric Oxide (NO) molecule plays a critical role in regulatory events associated with the cardiovascular system, protection of gastric mucosa, relaxation of the penile cavernosal smooth muscle underlying the erectile response, and signaling in the nervous system.

Encode Research is focusing its broad technology platform and expertise in Nitric Oxide (NO) chemistry and biology to develop new treatments and current therapies for genetic polymorphisms, and NO-related mechanisms in humans, which include adjuncts to fertility and male erectile dysfunction, as well as female-specific NO formulas.

Dr. Ann de Wees Allen, Chief of Biomedical Research at the Glycemic Research Institute in Washington, D.C. (Glycemic.com) is the lead scientist for the Encode Research Team.